Mutual Advisors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$577K Sell
3,775
-361
-9% -$55.3K 0.01% 816
2025
Q4
$570K Buy
4,136
+168
+4% +$22K 0.01% 822
2025
Q3
$522K Buy
3,968
+94
+2% +$11.5K 0.01% 835
2025
Q2
$456K Sell
3,874
-5,029
-56% -$567K 0.01% 828
2025
Q1
$998K Buy
8,903
+14
+0.2% +$1.49K 0.03% 445
2024
Q4
$870K Buy
8,889
+62
+0.7% +$6.61K 0.03% 524
2024
Q3
$999K Sell
8,827
-1,945
-18% -$221K 0.03% 485
2024
Q2
$1.19M Sell
10,772
-72
-0.7% -$7.23K 0.04% 429
2024
Q1
$1.05M Buy
10,844
+1,672
+18% +$171K 0.03% 458
2023
Q4
$926K Sell
9,172
-2,102
-19% -$203K 0.03% 475
2023
Q3
$1.15M Sell
11,274
-1,197
-10% -$122K 0.04% 381
2023
Q2
$1.26M Buy
12,471
+3,232
+35% +$323K 0.05% 370
2023
Q1
$850K Sell
9,239
-283
-3% -$24.7K 0.03% 471
2022
Q4
$864K Buy
9,522
+69
+0.7% +$5.81K 0.04% 447
2022
Q3
$719K Sell
9,453
-1,788
-16% -$148K 0.04% 461
2022
Q2
$950K Sell
11,241
-183
-2% -$16.1K 0.06% 353
2022
Q1
$1M Sell
11,424
-596
-5% -$51.6K 0.06% 377
2021
Q4
$1.05M Buy
12,020
+507
+4% +$42.1K 0.06% 367
2021
Q3
$942K Buy
11,513
+644
+6% +$57.9K 0.06% 370
2021
Q2
$992K Buy
10,869
+688
+7% +$61.3K 0.06% 356
2021
Q1
$870K Sell
10,181
-971
-9% -$87.1K 0.06% 354
2020
Q4
$1.05M Sell
11,152
-634
-5% -$55.4K 0.08% 291
2020
Q3
$1.02M Sell
11,786
-177
-1% -$15.3K 0.09% 245
2020
Q2
$1.04M Buy
11,963
+73
+0.6% +$6.3K 0.1% 215
2020
Q1
$980K Sell
11,890
-171
-1% -$15.3K 0.13% 179
2019
Q4
$1.14M Buy
12,061
+275
+2% +$24.7K 0.12% 207
2019
Q3
$1.02M Sell
11,786
-196
-2% -$17.6K 0.14% 187
2019
Q2
$1.09M Sell
11,982
-608
-5% -$51.5K 0.14% 185
2019
Q1
$1.08M Buy
12,590
+243
+2% +$19.5K 0.16% 157
2018
Q4
$949K Sell
12,347
-427
-3% -$33.2K 0.19% 135
2018
Q3
$986K Buy
12,774
+3,292
+35% +$243K 0.15% 166
2018
Q2
$642K Buy
9,482
+330
+4% +$22.8K 0.15% 205
2018
Q1
$663K Buy
9,152
+871
+11% +$66.3K 0.17% 201
2017
Q4
$623K Buy
+8,281
New +$625K 0.24% 124

Other funds holding NVS

Mutual Advisors's NVS Position: Q1 2026 in Review

Mutual Advisors reduced its Novartis (NVS) stake by 8.7% in Q1 2026, selling an estimated $55.3K and leaving 3,775 shares worth $577K. The position accounts for 0.01% of the portfolio, ranked #816.

Mutual Advisors first reported a position in NVS in Q4 2017 and has held it in 34 quarters since. The position peaked at $1.26M in Q2 2023. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Mutual Advisors held 3,775 shares of Novartis worth $577K as of Q1 2026.
  • Mutual Advisors sold 361 Novartis shares in Q1 2026, an estimated $55.3K.
  • Novartis made up 0.01% of Mutual Advisors's portfolio in Q1 2026, its #816 holding.
  • Mutual Advisors first reported a position in Novartis in Q4 2017 and has held it in 34 quarters since.
  • Mutual Advisors's Novartis position peaked at $1.26M in Q2 2023.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Mutual Advisors's 13F filing for Q1 2026, filed 4 May 2026.